JP2006519875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006519875A5 JP2006519875A5 JP2006509174A JP2006509174A JP2006519875A5 JP 2006519875 A5 JP2006519875 A5 JP 2006519875A5 JP 2006509174 A JP2006509174 A JP 2006509174A JP 2006509174 A JP2006509174 A JP 2006509174A JP 2006519875 A5 JP2006519875 A5 JP 2006519875A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- carbon atoms
- composition according
- disease
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims description 50
- -1 3-ethoxy-4-methoxy-phenyl Chemical group 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- VBWIZSYFQSOUFQ-UHFFFAOYSA-N cyclohexanecarbonitrile Chemical compound N#CC1CCCCC1 VBWIZSYFQSOUFQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 239000003112 inhibitor Substances 0.000 claims 14
- 102000004127 Cytokines Human genes 0.000 claims 13
- 108090000695 Cytokines Proteins 0.000 claims 13
- 208000015114 central nervous system disease Diseases 0.000 claims 13
- 208000018737 Parkinson disease Diseases 0.000 claims 10
- 239000004480 active ingredient Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 claims 6
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 6
- 206010034010 Parkinsonism Diseases 0.000 claims 6
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 claims 6
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 6
- 208000012902 Nervous system disease Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 208000014094 Dystonic disease Diseases 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000010118 dystonia Diseases 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims 3
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims 3
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 3
- 108010062431 Monoamine oxidase Proteins 0.000 claims 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 3
- 229960003805 amantadine Drugs 0.000 claims 3
- 230000003474 anti-emetic effect Effects 0.000 claims 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims 3
- 239000002111 antiemetic agent Substances 0.000 claims 3
- 229940125683 antiemetic agent Drugs 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 2
- 206010008748 Chorea Diseases 0.000 claims 2
- 208000003098 Ganglion Cysts Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 208000020764 Sensation disease Diseases 0.000 claims 2
- 208000005400 Synovial Cyst Diseases 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 206010068100 Vascular parkinsonism Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 2
- 208000012601 choreatic disease Diseases 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical group OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000006517 essential tremor Diseases 0.000 claims 2
- 230000005021 gait Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000007787 long-term memory Effects 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 230000002151 myoclonic effect Effects 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 230000001953 sensory effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000037418 vocal dysfunction Effects 0.000 claims 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45237403P | 2003-03-06 | 2003-03-06 | |
| PCT/US2004/006782 WO2004080393A2 (en) | 2003-03-06 | 2004-03-05 | Selective cytokine inhibitory drugs for treating disorders of the central nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006519875A JP2006519875A (ja) | 2006-08-31 |
| JP2006519875A5 true JP2006519875A5 (enExample) | 2006-10-12 |
Family
ID=32990646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509174A Pending JP2006519875A (ja) | 2003-03-06 | 2004-03-05 | 中枢神経系障害を治療するための選択的サイトカイン阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1605935A4 (enExample) |
| JP (1) | JP2006519875A (enExample) |
| KR (1) | KR100831545B1 (enExample) |
| CN (1) | CN1780616B (enExample) |
| AU (1) | AU2004220607B2 (enExample) |
| BR (1) | BRPI0408113A (enExample) |
| CA (1) | CA2517845A1 (enExample) |
| IL (1) | IL170710A0 (enExample) |
| MX (1) | MXPA05009435A (enExample) |
| NZ (1) | NZ542408A (enExample) |
| WO (1) | WO2004080393A2 (enExample) |
| ZA (1) | ZA200507322B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| CN109662964A (zh) | 2010-02-09 | 2019-04-23 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| JP2017141222A (ja) * | 2016-02-09 | 2017-08-17 | 国立大学法人帯広畜産大学 | パーキンソン病に併発した認知障害の治療剤及びそのスクリーニング方法 |
| RU2763425C2 (ru) * | 2017-10-18 | 2021-12-29 | Интрабио Лимитед | Терапевтические агенты для нейродегенеративных заболеваний |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
| JP2023549174A (ja) * | 2020-11-04 | 2023-11-22 | グリアセルテック・インコーポレイテッド | クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物 |
| CN119280228B (zh) * | 2024-11-06 | 2025-09-19 | 桂林医学院附属医院 | 帕金森病神经保护作用药物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| AR003951A1 (es) * | 1995-05-26 | 1998-09-30 | Pfizer | Formulacion farmaceutica sinergica para el tratamiento de la enfermedad de parkinson y composiciones para prepararla. |
| US5728845A (en) * | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic nitriles |
| JP3568749B2 (ja) * | 1996-12-17 | 2004-09-22 | 株式会社デンソー | 半導体のドライエッチング方法 |
| PT1035848E (pt) * | 1997-07-31 | 2003-09-30 | Celgene Corp | Acidos alcano-hidroxamicos substituidos e metodo de reducao dos niveis de tnf alfa |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US6471961B1 (en) * | 1999-02-24 | 2002-10-29 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
| US20020131954A1 (en) * | 2000-05-02 | 2002-09-19 | Tobinick Edward L. | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| AU2003222034A1 (en) * | 2002-03-20 | 2003-10-08 | Celgene Corporation | (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| AU2003262187A1 (en) * | 2002-04-12 | 2003-10-27 | Celgene Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
-
2004
- 2004-03-05 MX MXPA05009435A patent/MXPA05009435A/es not_active Application Discontinuation
- 2004-03-05 EP EP04717992A patent/EP1605935A4/en not_active Withdrawn
- 2004-03-05 AU AU2004220607A patent/AU2004220607B2/en not_active Ceased
- 2004-03-05 CN CN2004800118192A patent/CN1780616B/zh not_active Expired - Fee Related
- 2004-03-05 BR BRPI0408113-7A patent/BRPI0408113A/pt not_active IP Right Cessation
- 2004-03-05 KR KR1020057016598A patent/KR100831545B1/ko not_active Expired - Fee Related
- 2004-03-05 WO PCT/US2004/006782 patent/WO2004080393A2/en not_active Ceased
- 2004-03-05 CA CA002517845A patent/CA2517845A1/en not_active Abandoned
- 2004-03-05 JP JP2006509174A patent/JP2006519875A/ja active Pending
- 2004-03-05 ZA ZA200507322A patent/ZA200507322B/en unknown
- 2004-03-05 NZ NZ542408A patent/NZ542408A/en unknown
-
2005
- 2005-09-06 IL IL170710A patent/IL170710A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006519875A5 (enExample) | ||
| JP4897679B2 (ja) | インドロン誘導体、その製造方法及びその使用 | |
| CN1893934A (zh) | 1－磷酸－鞘氨醇（s1p）受体激动剂用于治疗脑变性性疾病的应用 | |
| CN1575170A (zh) | (－)－1－(3,4－二氯苯基)－3－氮杂二环[3.1.0]己烷及其组合物和作为多巴胺再摄取抑制剂的应用 | |
| RU2005103398A (ru) | Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона | |
| US20050107356A1 (en) | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | |
| US6620851B2 (en) | Methods for the treatment of neuropathic pain and other disorders using R(−)-ketoprofen | |
| JP2008523102A5 (enExample) | ||
| US20220062279A1 (en) | Treatment of movement disorders | |
| RU2374228C2 (ru) | Производные 4-фенилпиперидина в качестве ингибиторов ренина | |
| JP2008518924A5 (enExample) | ||
| AU737590B2 (en) | Use of mirtazapine for treating sleep apneas | |
| JP2005508363A5 (enExample) | ||
| ZA200507322B (en) | Selective cytokine inhibitory drugs for treating disorders of the central nervous system | |
| RU2003101396A (ru) | Замещенные нитрированные катехолы, их применение в лечении некоторых расстройств центральной и периферической нервной системы и содержащие их фармацевтические композиции | |
| EP1251842B1 (fr) | Utilisation du modafinil pour l'obtention d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies | |
| CN113194955A (zh) | 新用途 | |
| CN1104018A (zh) | 取代的(芳烷基氨基苄基)氨基丙酰胺衍生物及其制备方法 | |
| AU2001284234B2 (en) | The treatment of inflammatory disorders | |
| FR2684552A1 (fr) | Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants. | |
| JP2007526920A (ja) | 中枢神経系の障害の治療および管理のための選択的サイトカイン阻害剤を含む組成物ならびにその使用方法 | |
| FR2787713A1 (fr) | Composition en tant que medicament et utilisation d'une telle composition pour l'obtention d'un medicament destine a l'anesthesie, notamment medicament analgesique | |
| JP2002501045A5 (enExample) | ||
| JP2007063278A (ja) | うつ病、不安症および認知障害用の５−ｈｔ１ｂアンタゴニスト組成物 | |
| FR2774596A1 (fr) | Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer |